摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Butanol-2 2,3-dimethyl, 3-methoxy | 51936-09-5

中文名称
——
中文别名
——
英文名称
Butanol-2 2,3-dimethyl, 3-methoxy
英文别名
3-methoxy-2,3-dimethyl-2-butanol;pinacol monomethyl ether;3-methoxy-2,3-dimethyl-butan-2-ol;pinaconemonomethyl ether;Pinakonmonomethylaether;2-Hydroxy-3-methoxy-2,3-dimethylbutan;3-methoxy-2,3-dimethylbutan-2-ol
Butanol-2 2,3-dimethyl, 3-methoxy化学式
CAS
51936-09-5
化学式
C7H16O2
mdl
——
分子量
132.203
InChiKey
YRLVFWDTEUVAHM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    140.9±8.0 °C(Predicted)
  • 密度:
    0.892±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Butanol-2 2,3-dimethyl, 3-methoxy 生成 2-methoxy-2,3-dimethyl-3-nitrooxy-butane
    参考文献:
    名称:
    Formation of nitrate esters in thallium(III) nitrate oxidation of alkenes
    摘要:
    DOI:
    10.1021/jo00932a017
  • 作为产物:
    参考文献:
    名称:
    Hydrogen-bonding in non-cyclic vicinal diols and their mono-methyl ethers: an ftir study
    摘要:
    Thirteen vicinal diols and their mono-alkyl ethers, dissolved in CCl4 and CS2, have been studied in the fundamental OH-stretching region. These systems are predominantly present in the intramolecular H-bonded form. The frequency of the OH donor appears to be mainly determined by two effects: the character of the donor and its molecular surroundings. The frequency decreases on going over from primary to secondary and tertiary OH groups. The difference in the molecular surroundings is related to shielding of the H bond from the solvent and is expressed in a decrease of the frequency. For the diols evidence is found for a double, cyclic intramolecular H bond next to a single H bond in which one OH acts as a donor and another one as an acceptor. The proton of an acceptor OH is present in a preferential position and the corresponding OH frequency is increased with respect to the mono-hydroxy analogue.
    DOI:
    10.1016/0022-2860(91)87029-h
点击查看最新优质反应信息

文献信息

  • [EN] [1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA<br/>[FR] DÉRIVÉS DE [1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL]-PHÉNYLE OU -PYRIDIN-2-YLE EN TANT QU'INHIBITEURS DE LA PROTÉINE KINASE C-THÊTA
    申请人:VERTEX PHARMA
    公开号:WO2009073300A1
    公开(公告)日:2009-06-11
    The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R1, R2, R3, R4, R5, R6, R7, x and y are as described herein.
    本发明涉及式(I)和(IA)的化合物,可用作蛋白激酶(1a)的抑制剂。该发明还提供包括所述化合物的药学上可接受的组合物,以及使用这些组合物治疗各种疾病、症状或紊乱的方法。该发明还提供制备本发明化合物的方法。(a):特别是蛋白激酶Cθ,其中A和A'独立地为-N-或-C(R+) -。环B是五元或六元饱和碳环或杂环,R1、R2、R3、R4、R5、R6、R7、x和y如本文所述。
  • [EN] HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION COMME MÉDICAMENTS THÉRAPEUTIQUES
    申请人:DONG-A SOCIO HOLDINGS CO LTD
    公开号:WO2017039331A1
    公开(公告)日:2017-03-09
    The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
    本发明提供了一种杂环化合物、其立体异构体、对映异构体或药用可接受的盐,这些化合物能够调节Mer受体酪氨酸激酶(MERTK)的活性。本发明还提供了这些化合物的药物组合物、制备所述化合物的方法以及将这些化合物用作药物的应用。本发明针对的是具有显著活性的MERTK抑制性化合物,因此具有在癌症和任何与MERTK调控失调相关的疾病中进行药物干预的卓越潜力。
  • [EN] PYRAZOLE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS PYRAZOLE COMME INHIBITEURS JAK
    申请人:ALMIRALL SA
    公开号:WO2011101161A1
    公开(公告)日:2011-08-25
    New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    新的吡唑衍生物具有化学结构公式(I),公开了它们的制备方法,包括含有它们的药物组合物以及它们作为Janus激酶(JAK)抑制剂在治疗中的用途。
  • [EN] ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF<br/>[FR] ARYLE, HÉTÉROARYLE ET TÉTRAHYDROISOQUINOLINES À HÉTÉROCYCLE SUBSTITUÉ ET LEUR UTILISATION
    申请人:ALBANY MOLECULAR RES INC
    公开号:WO2010132437A1
    公开(公告)日:2010-11-18
    Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.
    本发明描述了新颖的芳基、杂芳基和非芳香杂环取代的四氢异喹啉化合物。这些化合物用于治疗各种神经和生理疾病。本发明还描述了制备这些化合物的方法。
  • [EN] 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS<br/>[FR] 2-AMINO-PYRIMIDINES 4,6-DISUBSTITUÉES, CONVENANT COMME MODULATEURS DU RÉCEPTEUR H4 DE L'HISTAMINE
    申请人:INCYTE CORP
    公开号:WO2010075270A1
    公开(公告)日:2010-07-01
    The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.
    本发明涉及式(I)的取代杂环化合物或其药用可接受的盐或N-氧化物或季铵盐,其中所述成员在此提供,并且它们的组合物和使用方法,这些化合物是组织胺H4受体抑制剂/拮抗剂,用于治疗组织胺H4受体相关疾病或疾病或疾病,例如,炎症性疾病或疾病,瘙痒和疼痛。
查看更多